APA (7th ed.) Citation

Wu, J. T., Cheuk, A., Isanogle, K., Robinson, C., Zhang, X., Ceribelli, M., . . . Khan, J. (2023). Preclinical Evaluation of the FGFR-Family Inhibitor Futibatinib for Pediatric Rhabdomyosarcoma. Cancers, 15(16), 4034. https://doi.org/10.3390/cancers15164034

Chicago Style (17th ed.) Citation

Wu, Jerry T., et al. "Preclinical Evaluation of the FGFR-Family Inhibitor Futibatinib for Pediatric Rhabdomyosarcoma." Cancers 15, no. 16 (2023): 4034. https://doi.org/10.3390/cancers15164034.

MLA (9th ed.) Citation

Wu, Jerry T., et al. "Preclinical Evaluation of the FGFR-Family Inhibitor Futibatinib for Pediatric Rhabdomyosarcoma." Cancers, vol. 15, no. 16, 2023, p. 4034, https://doi.org/10.3390/cancers15164034.